Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

  • STATUS
    Recruiting
  • days left to enroll
    41
  • participants needed
    330
  • sponsor
    Arena Pharmaceuticals
Updated on 15 September 2021
Investigator
Arena CT.gov Administrator
Primary Contact
Clinical Center " Dr Dragisa Misovic Dedinje" (3.7 mi away) Contact
+438 other location
remission
endoscopy

Summary

The purpose of this study is to assess the efficacy of etrasimod on clinical remission in participants with moderately to severely active ulcerative colitis (UC).

Details
Condition Ulcerative Colitis, Ulcerative Colitis (Pediatric)
Treatment Placebo, Etrasimod
Clinical Study IdentifierNCT03996369
SponsorArena Pharmaceuticals
Last Modified on15 September 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note